J&J Extends Lifeline to Nanobiotix in Potential $1.8B Licensing Deal

Johnson & Johnson has capitalized on the shaky financial ground at French biotech Nanobiotix by licensing its lead product, NBTXR3, intended to enhance the efficacy of radiotherapy in various tumor types including head and neck cancer, under an agreement announced Monday.